论文部分内容阅读
目的 探讨血清白细胞介素 6与原发性肝癌发生、发展、转移、疗效及预后的关系。方法 采用ELISA法 (双抗体夹心酶联免疫吸附试验 )检测了 6 8例原发性肝癌患者和 15例良性肝肿瘤患者治疗前后及 32例肝硬化患者的血清IL 6含量 ,再进行比较分析。结果 原发性肝癌患者血清IL 6水平明显高于正常人、肝硬化及良性肝肿瘤患者 (P <0 .0 1) ,且与肿瘤直径、有无腹腔积液、有无肝外转移、临床分期及治疗效果有关 ,与血清AFP呈正相关。结论 原发性肝癌患者血清IL 6水平在一定程度上可反映肝癌发生、发展、转移情况及治疗效果 ,可能成为预测肝癌转移、复发及疗效的有效指标 ,与AFP同时检测 ,有望提高原发性肝癌的早期诊断。
Objective To investigate the relationship between serum interleukin-6 (IL-6) and the occurrence, development, metastasis, curative effect and prognosis of primary liver cancer. Methods Serum IL-6 levels were measured by ELISA (double antibody sandwich enzyme-linked immunosorbent assay) in 68 patients with primary liver cancer and 15 patients with benign liver tumor before and after treatment and in 32 patients with cirrhosis, and then compared and analyzed. Results The serum level of IL-6 in patients with primary hepatocellular carcinoma was significantly higher than that in patients with normal liver cirrhosis and benign liver tumors (P <0.01), and with tumor diameter, with or without extraperitoneal effusion, Staging and treatment effect, and serum AFP was positively correlated. Conclusion The serum level of IL-6 in patients with primary liver cancer may reflect the occurrence, development, metastasis and therapeutic effect of hepatocellular carcinoma to a certain extent, which may be an effective index to predict the metastasis, recurrence and curative effect of liver cancer. Simultaneous detection with primary AFP may improve the primary Early diagnosis of liver cancer.